Format

Send to

Choose Destination
See comment in PubMed Commons below
J Dermatolog Treat. 2006;17(3):151-3.

The efficacy of combined PUVA and low-dose azathioprine for early and enhanced repigmentation in vitiligo patients.

Author information

1
Department of Dermatology, Jondishapour Hospital, Jondishapour University of Medical Sciences, Ahwaz, Iran. radmanesh_m@yahoo.com

Abstract

BACKGROUND:

Immunosuppressive agents are used widely in the treatment of vitiligo. Corticosteroids are used either alone or as adjuvant therapy by many practitioners. Cyclophosphamide and cycloporine-A have also been used with variable success. Azathioprine may have the potential for the treatment of vitiligo alone or in combination with other modalities.

OBJECTIVE:

To compare the efficacy of combined low-dose azathioprine and oral PUVA therapy versus oral PUVA therapy alone for the treatment of vitiligo.

PATIENTS AND METHODS:

A total of 60 vitiligo patients were randomized to receive either azathioprine (0.6-0.75 mg/kg) and oral PUVA therapy (group 1) or oral PUVA therapy alone (group 2). Patients were followed for 4 months. A graph transparency with squares of 2.5 x 2.5 mm was used to measure the rate of repigmentation after 4 months of therapy.

RESULTS:

Perifollicular repigmentation started after a mean of five sessions in group 1, and eight sessions in group 2. The mean total repigmentation rate after 4 months was 58.4% for group 1 and 24.8% for group 2. No serious side effects were seen during or after treatment.

CONCLUSION:

Azathioprine may potentiate the repigmentary effects of PUVA therapy in vitiligo patients. A limitation of the study is the lack of validated measures for vitiligo assessment.

PMID:
16854754
DOI:
10.1080/09546630600791442
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center